BMT CTN Protocol 1201 (Alliance A051301)

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma of the Activated B-cell Subtype

Below are protocol-related documents, which may be periodically updated.

             Protocol Chair: Charalambos Babis Andreadis, MD, MSCE:    

             BMT CTN Protocol Chair: Timothy Fenske, MD:

             Protocol Coordinator: Amy Foley:



For the Alliance A051301/BMT CTN 1201 study, centers participate via their NCTN group. The protocol may be accessed through the CTSU website: For questions, contact the CTSU Help Desk: or 1-888-823-5923.